
Just over 60% of 61 people recently diagnosed with pancreatic cancer that had spread saw their tumours shrink or disappear after taking daraxonrasib alongside chemotherapy, the BBC reports. For around 8% of all participants, or one in 12, CT scans could no longer detect a tumour.
Researchers are presenting the early trial results at a European cancer conference. They reported that tumours stopped growing in 90% of participants. That figure includes people whose tumours shrank as well as those whose disease held steady. Likewise, the one in 12 whose scans showed no tumour are part of the group whose tumours shrank or disappeared, not an additional group.
Daraxonrasib is a daily pill that targets RAS mutations, which drive tumour growth in most pancreatic cancers. Chemotherapy itself can shrink tumours, so the figures describe the response to the combination, not the effect of the pill alone.
The trial followed participants for an average of 18 months. Dr Wungki Park, one of the researchers, said the depth of the responses and the time the disease stayed under control were encouraging. The distinction that matters for patients is between what a scan shows today and what happens afterwards: cancer can return even when it is no longer visible. Longer studies will help show how long the responses last and whether patients live longer.
Sources
- BBC UK · Source date: 2026-11-20
Independent editorial content. WUA is not affiliated with any political party. 2026-11-20